References
- Organisation for Economic Co-operation and Development. Health at a Glance 2015: OECD Indicators 2015 [ Cited 2016 Apr 3]. Available from: http://www.keepeek.com/Digital-Asset-Management/oecd/social-issues-migration-health/health-at-a-glance-2015_health_glance-2015-en.
- Leopold C, Zhang F, Mantel-Teeuwisse AK, et al. Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. Int J Equity Health. 2014;13:53.
- Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol. 2010;1: 1–16. Epub 2010/01/01.
- Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:1–9.
- Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J Generic Med. 2006;3(4):257–268.
- van Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res. 2012;1:527–538.
- Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol. 2010;1: 141. Epub 2010/01/01.
- Australian Government Department of Health and Ageing. The Impact of PBS Reform. Commonwealth of Australia, Canberra; 2010.
- Law MR, Kratzer J. The road to competitive generic drug prices in Canada. CMAJ: Can Med Assoc J. 2013;185: 1141–1144. Epub 2012/11/21.
- Österreichisches Bundesinstitut für Gesundheitswesen. Surveying, assessing and analysing the pharmaceutical sector in the 25 EU Member States. European Communities, Luxembourg; 2006.
- Organisation for Economic Co-operation and Development. Health at a Glance 2013: OECD Indicators 2013 [Cited 2015 Jun 15]. Available from: http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf.
- The Centre for Strategic Economic Studies. The impact of PBS reforms on PBS expenditure and savings. Melbourne: Victoria University; 2009.
- Kanavos P, Costa-Font J, Seeley E, et al. Competition in off-patent drug markets: issues, regulation and evidence. Econ Policy. 2008;23(55):500–544.
- Brekke KR, Holmas TH, Straume OR Are pharmaceuticals still inexpensive in Norway? A comparison of prices of prescription pharmaceuticals between Norway and Nine West European countries. SNF Report No. 05/08. Bergen: The Institute for Research and Economics and Business Administration, 2010.
- Dylst P, Simoens S. Does the market share of generic medicines influence the price level? A European analysis. Pharmacoeconomics. 2011;29: 875–882. Epub 2011/07/30.
- Simoens S. International comparison of generic medicine prices. Curr Med Res Opin. 2007;23: 2647–2654. Epub 2007/09/20.
- Duckett SJ, Breadon P, Ginnivan L, et al. Australia’s bad drug deal: high pharmaceutical prices. Melbourne: Grattan Institute; 2013.
- Mansfield SJ. Generic drug prices and policy in Australia: room for improvement? A comparative analysis with England. Aust Health Rev. 2014;38: 6–15. Epub 2014/02/01.
- Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Med J Aust. 2010;192: 633–636. Epub 2010/06/10.
- Vogler S, Kilpatrick K, Babar Z-U-D. Analysis of medicine Prices in New Zealand and 16 European countries. Value in Health. 2015;18:484–492.
- Clarke PM. The pricing of statins and implications for pharmaceutical benefits scheme expenditure. Med J Aust. 2013;198: 260. Epub 2013/03/19.
- Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8:7–24.
- Dylst P, Vulto A, Simoens S. Analysis of French generic medicines retail market: why the use of generic medicines is limited. Expert Rev Pharmacoecon Outcomes Res. 2014;14:795–803.
- McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10:73–85.
- Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res. 2013;13: 59–72. Epub 2013/02/14.
- Chevreul K, Berg Brigham K, Durand-Zaleski I, et al. France: health system review. Health Syst Transit. 2015;17:1–218.
- Live PM. UK statin prescribing set for ‘mass shift’ to generic lipitor 2012 [2017 Jan 14]. Available from: http://www.pmlive.com/pharma_news/lipitor_patent_loss_atorvastatin_uk_378045.
- Generics and biosimilars initiative. Sanofi France to make generic atorvastatin 2011 [Cited 2017 Jan 14]. Available from: http://www.gabionline.net/Generics/News/Sanofi-France-to-make-generic-atorvastatin.
- National Health Service. NHS electronic drug tariff 2017 [Cited 2017 Jan 14]. Available from: http://www.drugtariff.nhsbsa.nhs.uk/#/00429017-DC/DC00428369/Part VIIIA products R.
- Drugs.com. Patent expirations through 2016 predicted to lower brand spending by $127 Billion 2014 [Cited 2017 Jan 14]. Available from: https://www.drugs.com/article/patent-expirations.html.
- Jackevicius CA, Chou MM, Ross JS, et al. Generic atorvastatin and health care costs. N Engl J Med. 2012;366: 201–204. Epub 2011/12/14.
- Bennie M, Godman B, Bishop I, et al. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12: 125–130. Epub 2012/01/28.
- Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10:707–722.
- L’assurance maladie caisse nationales. Rapport d’activité 2014 La santé pour tous Nos engagements et nos résultats 2014 [Cited 2014 Apr 3]. Available from: http://www.ameli.fr/fileadmin/user_upload/documents/rapport_activite_2014.pdf.
- Gesundheit Bf. EU -Durchschnittspreise loud ASVG 2015 [Cited 2015 Aug 15]. Available from: http://bmg.gv.at/home/Schwerpunkte/Medizin/Arzneimittel/Arzneimittelpreise/EU-Durchschnittspreise_laut_ASVG.
- Organisation for Economic Co-operation and Development. 4. PPPs and exchange rates 2015 [Cited 2015 Feb 10]. Available from: http://stats.oecd.org/index.aspx?DataSetCode=SNA_TABLE4.
- Office for National Statistics. CPI all items index: estimated pre-97 2015=100 2015 [Cited 2016 May 29]. Available from: https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/d7bt.
- Institut national de la statistique et des études économiques. Indice des prix à la consommation - Base 2015 - Ensemble des ménages - France - Ensemble hors tabac 2015 [Cited 2016 May 29]. Available from: http://www.bdm.insee.fr/bdm2/affichageSeries.action?request_locale=fr&recherche=idbank&idbank=001763852.
- Statistics New Zealand. Group: consumers Price Index - CPI 2015 [Cited 2016 May 29]. Available from: http://www.stats.govt.nz/infoshare/ViewTable.aspx?pxID=d7dd950c-4207-4dcb-b84a-cb65824a4d3c.
- Australian Bureau of Statistics. 6401.0 - consumer price index, Australia, Dec 2013 2014 [Cited 2016 May 29]. Available from: http://www.ausstats.abs.gov.au/ausstats/meisubs.nsf/0/418302CC34F569FCCA257C67000CE6D7/$File/64010_dec%202013.pdf.
- Committee for Economic Development of Australia. Healthcare: Reform or ration. 2013 April.
- Babar Z. Pharmaceutical prices in the 21st century. Springer International Publishing, Switzerland; 2015.
- Australian Government Department of Health. Report on the collection of under co-payment data 2013-14 2015 [Cited 2015 Feb 15]. Available from: http://www.pbs.gov.au/info/statistics/under-co-payment/ucp-data-report.
- Thai LP, Vitry AI, Moss JR. Pricing and utilisation of proton pump inhibitors in South Australian public hospitals and the pharmaceutical benefits scheme. J Pharm Pract Res. 2016;46:130–136.
- Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10: 153. Epub 2010/06/10.
- Godman B, Schwabe U, Selke G, et al. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics. 2009;27: 435–438. Epub 2009/07/10.
- Pichetti S, Sermet C, Godman B, et al. Multilevel analysis of the influence of patients’ and general practitioners’ characteristics on patented versus multiple-sourced statin prescribing in France. Appl Health Econ Health Policy. 2013;11:205–218.
- Australian Government Department of Health and Ageing. Review of Statin therapies 2012 [Cited 2013 Jul 12]. Available from: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2012-07/review-of-statin-therapies.
- Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental decrease in end points through aggressive lipid lowering study g. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Jama. 2005;294:2437–2445.
- Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35:139–151.
- Soran H, Durrington P. Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother. 2008;9:2145–2160.
- Morrissey RP, Diamond GA, Kaul S. Statins in acute coronary syndromes: do the guideline recommendations match the evidence? J Am Coll Cardiol. 2009;54:1425–1433.
- Neumann A, Maura G, Weill A, et al. Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. Pharmacoepidemiol Drug Saf. 2014;23:240–250.
- Ragupathy R, Aaltonen K, Tordoff J, et al. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics. 2012;30: 1051–1065. Epub 2012/09/12.
- Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. New Zealand Med J. 2011;124: 12–28. Epub 2011/12/07.
- Babar Z, Vitry A. Differences in Australian and New Zealand medicines funding policies. Australian Prescriber. 2014;37:150–151.
- Ragupathy Y. New Zealanders’ access to licensed and subsidised medicines compared with a nationwide single payer system in each of Australia. the United Kingdom and the United States: University of Otago; 2013.
- Australian Government Department of Health. Report to Parliament on the Collection of PBS/RPBS under Co-payment Prescription Data 2012-13. 2014.